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Abstract
THE EFFECTS OF BIOLOGICAL RESPONSE MODIFICATION 




The effect that diet and other modifiers may have upon the immune 
system of BALB/c mice bearing tumor were studied, 
mice were injected s.c. with 10^ herpes simplex virus Type 2-
Adult male BALB/c
transformed (H238) cells in the thigh causing a visible fibrosarcoma
within 1-2 weeks. Mice were fed either a diet low in protein (milk)
and low in fat (Diet 1), or another diet low in protein (wheat) and
high in fat (Diet 8). Spleen cells were collected for assays of
cytotoxic T-lynphocyte (CTL) and natural killer (NK) cell activity. At
3 weeks post-injection, a decrease in CTL activity against H238 tumor
cells was observed but no change in NK activity against H238 or K562
Spleen cells were treated In vitro with mousetargets was seen.
interferon, rat interleukin-2, 2-amino-5-bromo-6-methyl-4-pyrimidinone 
(ABMP), Prostaglandin E^ (PGE-^) , singly and in combination, for 2 hours 
prior to mixing with target cells. Treated spleen cells from Diet 1
tumor-bearing animals at 3-6 weeks post-injection had substantially
increased CIL response while those from Diet 8 mice were only
slightly enhanced. Interferon, interleukin-2 and prostaglandin E^ 
most effective. NK activity remained essentially unchanged regardless
were
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Diet ar,e Cancer. In recent years, much attention has been given to
the role of diet in carcinogenesis. Epidemiological studies implicate
diet as a factor in the development of tumors of the esophagus,
stomach, colon, breast, liver, skin, and various other organs in humans
(Lea, 1966; Carrol, 1975; Clayson, 1975).
The etiology of cancer is often attributed simply to
"environmental causes" . Host individuals do not realize that
"environmental causes" include dietary factors. It has been estimated
that up to 35% of all cancers may eventually be prevented by dietary
modification (Newell, 1983).
Geographical comparisons which indicate that there are wide
variations in cancer incidence from one country to another may well be
a function of diet. In certain western countries in which per capita
consumption of total dietary fat is high (approximately 4 0% of total
caloric intake), the incidence of breast and colon cancer is also high.
By contrast, m certain eastern countries where the intake of dietary
fat comprises only 10% of the total caloric intake, the incidence of
these two types of tumors is low (Armstrong and Doll, 1975; Carrol,
1975; Higginson, 1983).
The possible role of dietary fat in the induction of human cancer
of the large bowel has received support from experimental studies
(Howe et. al 1982). Rats fed either 20% lard or 20% corn oil were• >
more susceptible to colon tumor induction by 1,2- dimethyl hydrazine, a
chemical carcinogen, compared to those rats fed 5% lard or 5% corn oil
Reddy et. al., 1976d).
1
2
Evidence that dietary fat, as a primary etiological factor
(distinct from chemical contaminants of the diet and other
environmental and genetic factors) is an important determinant of
breast cancer risk is reinforced by a variety of epidemiological
(Carrol, 1975; Hopkins, 1976; flacMahon, 1978; Eniq, 1978; Cohen, 1982)
ana laboratory animal studies (Chan and Cohen, 1974; Chan, 1877;
1981; Dao and Chan, 1983) .Wetsel et. al Dietary fat has also been• r
shewn to play a role in pancreatic carcinogenesis (Dirt et. al., 1983).
It may be useful to differentiate between "initiation" and
"promotion" of neoplastic growth. Initiation refers to the primary
cause of the tumor, whereas promotion refers to various factors which
enhance the growth or spread of the primary tumor. Initiation is
apparently irreversible and may occur at any carcinogen dose level.
Promotion is dose and tine dependent (in a chemical carcinogen model)
and may be a reversible step in tumor development (Pitot, 1983). 
Dietary fat appears to affect primarily the promotional phase of
carcinogenesis (Carroll, 1981a, 1981b; Davidson and Carroll, 1982; Chan
and Dao, 1983; Kraft, 1983), but may also influence the initiation
phase as well.
There are numerous mechanisms whereby the level of dietary fat
intake can potentially affect tumor growth. Dietary fat increases bile
acid secretion and hence the amount of colonic bile acid metabolites
that are possible tumor-producing agents in colon cancer. Dietary
cereal bran and related fibers reduce the concentration of bile acids
and othe ■ compounds aSoOeiab.-d with neopl os in the large bowel and
appear to lower colon cancer risk in humans and animal models (Eurkitt,
3
Dietary tat also influences the synthesis and1980; Reddy, 1980).
release of prolactin, a potential laaiurary yiunu tuner promoter in boti
rats arid humans (Rose, 1979; Ready, 1980) . Dietary fat may also affect
the hormonal milieu within the breast with respect to steroid hormones
levels ana balances ana can near on the composition and physical
characteristics of membranes, thus influencing the interactions between
peptide hormones ana their membrane bound receptors (Wynder and Cohen,
The production of growth regulating substances such as1982) .
prostaglandins which are derivatives of dietary essential fatty acias,
Dietary fat canmay also be influenced by fat uptake (Ilorrobin, 1979) .
also affect tumor growth by impairing the function of the immune system
1983).(Levy and Ibrahim, 1982; Watson and Retro, 1983; Siegel et. al • r
That viruses are the etioiogicSignificance of the IISV-2 System.
agent of neoplasia in certain animals has long been an established 
As early as 1908 Ellerman and Bang showed that spontaneousf act.
leukemia in chickens was caused by a filterable agent suggesting that
Since that time many investigatorsit was probably caused by a virus.
(Rous, 1911; Shope, 1933; Lucke, 1934; Bittner, 1936; Gross, 1951) have
shewn certain animal tumors to be of viral origin.
Although it has not been demonstrated conclusively that any one
virus is a cause of cancer in man, several viruses have been found to
be associated with specific human cancers and are suspected of playing
As early as 1968 strong sero-a role in the etiology of cancer.
epidemiological evidence was found linking herpes simplex virus Type 2
(HSV-2) with carcinoma of the cervix (Rawls of. al., 1968). Major
associations continue to be suggested between carcinoma of the cervix
4
and 1ISV-2 (Pvawls ct. al., 1976; Harwiaa ot. al., 1976; I loll mgs beau ct.
ai., 1976), and huruan cervical tunor cells have been shown to contain
DhA sequences identical to sections of the F:SV-2 genome (Frenkel et.
It lias been shov/n thatal. , 1972; Roizman and Frenkel, 1973 ).
inactivated 11577-2 is capable of transforming hamster, mouse and human
embryonic fibroblasts to potentially malignant cell lines (Duff and
Rapp, 1971; Duff and Ra^p, 197 3; Rapp and Duff, 1974; Doyd and Crme,
In this stuay the 11238 tumor cell line v/as1975; Boyo, 1976).
transformed to malignancy using UV-inactivated herpes simplex virus
lype 2 (Boyd and Orme, 1975) .
Bioloqical Response Fiodifiers. Interferon, a glycoprotein of
molecular weight 20-30,000, is a highly active molecule both in terms 
of its direct anti-proliferative effects on tumor cells, (Evinger et.
al., 1581) and direct modulation of the host immune response (Paucker
Interferon may be one of the key1962; Finter, 1979) .et. al • t
regulatory substances for both cytotoxic lynphocytes and natural killer
197 9; Hi nat o e t. a 11978; Herberman et. alcells (Trincheri et al • t• /• f
1980; Targan and Dorsey, 1980). Cytotoxic T-lymphocytes, once
sensitized to tumor associateo antigens, can effectively destroy tumor
The natural killer cell,cells provided the host is immunocompetent.
despite its lack of imnunological memory, non-specifically recognizes
foreign cells and is thought to play a crucial role in primary
immunological surveillance, thereby providing a first line of defense
against tumors (Dennert, 1980; Herberman and Ortaldo, 1981). 
Enhancement of this arm of the immune response could result in a much
more efficient immune response against the tumor.
5
Interleukin-2 (IL-2) , a class of T-cell regulatory molecules, lias
been shov;n to trigger the clonal expansion of antigen or mitogen
activated T-cells (Baker et. al. , 1978; Watson, 1979; Suzuki et. al..
1983) Tills lynphokine will also provide that T-cell hielp necessary for
the generation of plaque forming cell responses from T-cell deficient
Interleukin-2 has beenlynphoio {.xjpuiations (Watson et. al. , 1979).
shown to promote the in vitro differentiation of antigen specific
cytotoxic T-lymphocytes (CTL) from nude mouse splenocytes (Gillis et. 
al., 1979) and immature thymocyte populations (Wagner and Rollinghoff,
Interleukin-2 has also been shown to augment natural killer1980).
cell activity in vitro (Henney et. al., 1981; Kuribayashi et. al • f
1981).
Prostaglandins are 20 carbon fatty acids which are products of the
arachidonic acid pathway; they are produced at the cellular level by a 
number of cell types including monocytes arid macrophages (Zeevi
1977; Bockman and Rothschild, 1979). The mechanisms of NK/CTLet. al • t
regulation as it relates to prostaglandin biosynthesis are poorly
understood. Certain prostaglandins have been shown to inhibit (Brunda
1980; Tracey and Atkinson, 1980; Koren, 1981) and others toet. al • t
1978) effector cell cytotoxicity towaraenhance (Gidlund et. al • f
Prostaglandin E^, has been shown to restore the 
ability of the suppressed, interferon-depleted cell to produce
labeled target cells.
interferon (St ring fellow, 1980) . Interferon and prostaglandins have
been shown to have a synergistic effect on NK lytic activation in terms
of enhanced capacity of effector-target lytic interactions when the 
proper temporal restrictions are observed (Targan, 1981).
6
2-arriino-5-bL'omo-6-ii!etLyl-4-pyrimidiono (AIf.P) is a compound
capable of causing spleen cells to produce endogenous interferon. A
form of this compound, ADPP (2-aruino-5-bromo-6-phenyl-4-pyrimioinone)
lias previously been used in our laboratory (Kettering et. al.,
submitted for publication) where it appeared to lower both tumor
incidence and tumor volume (as compared to control animals) when
administered jji vivo.
Previous work done in our laboratories. Previous studies in our
laboratories have investigated the ability of 14 different diets to
restrict or enhance tumor growth. These diets varieo in the level (11
or 33%) and source (milk, soy, wheat, fish, and beef) of protein and in
the level (5 or 30%) of fat (corn oil). From this study (Gridley et.
1982) the diet, found to be most restrictive toward the growth ofal • r
a UV inactivated herpes simplex Type 2 virus-transformed cell line
(H238) in BALB/c mice, containea a low level of fat (5%) with casein
(11%) as the protein source (Diet 1) while the diet which iriost enhanced
tumor growth contained a high level of fat (30%) with wheat gluten
(11%) as the protein source (Diet 8). Further studies utilizing these
2 diets (Diets 1 and 8) (Nutter et. al 1982) shaved that mice (with a• ?
progressively graving H238 cell tumor) fed Diet 8 (high fat with wheat
gluten as the protein source) had a diminished level of immunity
against the tumor target cells as compared to mice (also carrying a
progressing F1238 tumor) fed Diet 1 (low fat with casein as the protein
source). Additional work with the original 14 diets utilized a
chemically transformed tumor cell line (1,2-diinethylhydrazine (DHH) 
transformed #51 cells) in BALB/c mice (Nutter et al., 1983a) and
7
spontaneous mouse niainmary tumor virus in C3II mice (Griuley ct. al. ,
1983). These, stuuies shewea that a higher incidence and rate of growtl
v/as associated with Diet 8 while mice fed Diet 1 appeared to have a
lower tumor incidence and rate of tumor growth. The results from our
most recent dietary study (Nutter et. al 1983b) differ from those of• F
It was found that DM-i-injected F-ALB/c mice fed aour previous work.
casein diet had significantly higher tumor incidence and volume than
DMI-injected RALE/c mice fed a beef diet. In spite of the last study
(Nutter et. al., 1983b), these results present fairly solid evidence
for the low fat-casein diet (Diet 1) being more restrictive to tumor
growth than the high fat-wheat gluten diet (Diet 8).
The most recent study (Kettering et. al submitted for• r
publication) has centered around the jLn vivo effect of certain
biological response modifiers (levamisole, Corvnebacterium parvurn.
syngeneic unblocked lymphocytes, anti-blocking factor, and ABPP) on
H238 tumor cell-injected RALB/c mice. The only modifier used in this
previous study to be used in the present in. vitro study will be the
ABPP analog, ABMP.
The goal of this research ’project hasGoal of Research Project.
been to investigate the Jji vitro effect of certain biological response
modifiers on cytotoxic T-lynphocyte and natural killer responses using 
spleen cells from BALE/c mice fed the previously defined diets (Diets 1
and 8) ana injected with H238 tumor cells.
IiatenalL. ana iletnoas
Animals
A total of 512 five week ola male DALB/c mice were obtained from
Hie Jackson laboratory (Bar Harbor, Maine) . They were separated into
groups, marked with picric acid so that each mouse could be followed
throughout the entire study, and housed <5 to a cage. The mice were fed
a specified diet for 10 weeks prior to the beginning of the experiment
ana body weight was monitored on a weekly basis. The nontumor cell-
injected control mice, 2/cage, were housed with the tumor cell-injected 
mice, 6/cage. The mice were chosen at random on the day of testing
ana euthanized using dry ice.
Diet Composition
The two diets used in the study were composed as follows:
Diet 1 had 11% protein (casein source) and 5% fat (corn oil) . Diet 1
will refer to the low fat diet. Diet 8 also had 11% protein (wheat
gluten source) and 30% fat (corn oil). Diet 8 will refer to the high
fat diet. A non-nutritive filler, Celufil (U. S. Biochemiicals) was
used to make the diets isocaloric at 3.84 Kcals/gram. Dextrin (corn
starch) was the carbohydrate source in both diets. Each diet was
mineral mix (AIN-76) 3.5%, vitaminsupplemented with the following:
mix (AIN-76) 1%, choline bitartrate 0.2%, and D-L methionine at 0.3%.
In addition to this the wheat gluten was supplemented with appropriate
amounts of lysine and L-threonine.
Tumor Cell Lines
11238 Cells. A EALB/c mouse embryonic fibroblast cell line (238)
was originally transformed by UV inactivated herpes simplex virus Type
8
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2 (Savage strain) into a malignant tumor cell line (H230). Our
laboratory obtained the H238 cell line from Dr. Ann Boyd, National
Cancer Institute, Frederick, Naryland.
K562 Cells. This cell line was originally derived from a patient
with myelogenous leukemia. These cells are especially sensitive to
lysis by NT (natural killer) cells (Targan, 1981), possibly due to a
large amount of NIC target binding structure expressed on the surface of
the cell. Our laboratory obtained the K562 cell line from Dr. Steven
Targan, University of California at Los Angeles, Los Angeles,
California.
Hedia
H238 cells were grown in Dulbecco.'s Modified Eagle's Medium (Grand
Island Biological Conpany, Grand Island, New York) . K562 cells were
grown in Roswell Park Memorial Institute (RPMI) 1640 medium (Grand
RPMI-1640 was alsoIsland Biological Company, Grand Island, New York).
used in any procedure involving lymphocytes. Both media v/ere
supplemented with 10% fetal calf serum (Irvine Scientific Company,
Santa Ana, California), 100 units of Penicillin/ml (Pfizer, Inc New• r
York, New York), 100 micrograms/ml streptomycin (Eli Lilly and company,
Indianapolis, Indiana), and 100 micrograms/ml fungizone (E. R. Squibb
Princeton, New Jersey). All media were prepared inand Sons, Inc • /
double distilled water and filter sterilized.
Tumor Cell Injection
H238 cells of the same passage number were taken from liquid
nitrogen and split several times bn vitrc in order to obtain rapidly
The cells were then harvested bydividing cells of high viability.
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trypsinization, suspended, and v/ashed three tntes in TBS to remove any
conplete Dulbecco's mediuni [tris buffered saline tfie forn,ula for which
0.14 M KaCl, 5.1 mb KC1, 0.3 8 mlu Na2HP04 * 7H20, 0.56 nil 
dextrose (anhydrous), 0.0025 M Tr is-( hydroxymethyl) ami noruethane
and 0.9 nil CaCl^j.
follows:
(Schwartz/Mann), 0.018B HC1, 0.4S mb HgCl 2
The cells were counted in a hemocytonieter and adjusted in TBS to a 
concentration of 3.3 x 10^ cells/mi. l\ 1 ml tuberculin syringe was
used to make a 0.3 ml subcutaneous injection of the cell suspension
into the lateral portion of the right hind leg, delivering 
approximately 1 x 10^ cells/mouse.
Each cage contained 2 mice that did not receive tumor cell 
These mice were tested at the same time as the other miceinjection.
in the cage and their cells were used as a normal control in order to 
obtain baseline values for unstimulated cytotoxicity results in both
assay systems.
Labeling Target Cells.
! 251_The labeled compound used in all labeling procedures was
125 The H238 cells wereI-IdUrd, Amersham, England).rododeoxyuridine (
split 24 hours prior to labeling and cultured in 50% Dulbecco's
The K562 cellsconplete medium and 50% RPMI - 1640 complete medium, 
were split 24 hours prior to labeling, but were maintained in only RPMI-
The morning the cells were to be labeled they were1640 medium.
removed from the culture flasks (1123 8 cells via trypsinizat ion) and
again taken up in fresh medium, II238 cells in 50% Dulbecco's, 50% RPMI-
1640 medium and K562 cells in 100% RPMI-1640 medium. The cells were
ttien counted in a hemocytometer and adjusted to a final concentration
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of 1.6 x 10 ceils/iul in "conuitioneo" mcxjia, the actual ivicdia used to
culture the target cells 24 hours prior to trypsinization. Four rrl of
this cell suspension was added to 4 ml of label containing medium. The
—4latter was prepared by combining 0.42 ml of 10 ' of fluorodeoxyuridine
(FUciR) m RPIil - 1640 medium, 3.36 mi "conditioned" media and 0.48 mi
125 I-IdUrd (final concentration 3 microcuries/mi).of
For each cell type, 2 ml of the combined cell suspension ano
label containing medium was pipetted into each of 4 small tissue
culture flasks and incubated at 37 degrees centigrade in a 5% CC^
After this period the 11238 or K562 cells wereatmosphere for 4 hours.
treated differently.
The label-containing medium in which the cells were11238 colls.
cultured was gently poured off, and the cells attached to the bottom of
The cells werethe flask were washed 3 times with RPFI - 1640 medium.
then trypsinized off the bottom of the flask, resuspended in 10 ml RPMI
The supernatant was gently poured off-1640 medium, and centrifuged.
the cell button, and the cells were resuspended in 3 ml of RPI4I-1640
The cells were counted in a hemocytometer, and adjusted to a
A
final concentration of 5 x 10* cells/ml.
medium.
Since the K562 cell is not an adherent type, theK562 cells.
washing procedure had to be varied from that of the H23 8 cells. The
cells and label-containing medium in the test tubes was centrifuged,
Fresh RPMI-1640 medium wasana the supernatant gently pipetted off.
added and the procedure was repeated twice, for a total of 3 washes.
The cells were resuspended in 3 ml of RPMI-16 40 medium at the end of
The final cellthe third wash and counted m a heinocytometer.
12
4concentration was adjusted to 2.5 x 10J cells/rnl.
Effector Cells
Spleens were removed from all test and control animals and placed
The spleens were then teased with woodenin 3 ml of RPMI-1640 medium.
applicator sticks until the cells were released. The suspensions were
Ammonium chloridecentrifuged and the supernatants discarded.
0.01 M KHCOv
0.16 M MI^Cl and 0.1 mil Isfc^EDTA) was added to remove red blood cells. 
The WBC+RBC/ACK suspension (white blood cell + red blood cell) was 
incubated for 4 minutes at 4 degrees centigrade.
potassium (ACK) lysing buffer (ACK formula as follows:
The tubes were
centrifuged again and the supernatant discarded. The remaining cells
(effector cells) were resuspended in RPMI-1640 medium, counted in a
6hemocytometer and adjusted to a final concentration of 6.0 x 10 viable
cells/ml, using 0.2% trypan blue as an indicator of cell viability. 
The term "effector cell" is used to indicate any lymphocyte derived
It should be recognized that all thefrom the spleen of the mouse.
lynphocytes included in the "effector" category will not be active
against target cells.
In Vitro Treatment of Effector Cells
The effector spleen cells, prepared as outlined above, were pooled
according to the following major grouping.
1) Diet 1, non tumor cell-injected mouse spleen cells (control)
2) Diet 1, tumor cell-injected mouse spleen cells
3) Diet 8, non tumor cell-injected mouse spleen cells (control)
4) Diet 8, tumor cell-injected mouse spleen cells 
Aliquots (1 ml) of each of the 4 groups were treated with various
13
concentrations and combinations of the following biological response
modifiers: Mouse alpha and beta interferon (Lee Biomolecular Research,
San Diego, California), ABKP (Sigma Chemicals, St. Louis,Inc • r
Misouri), Interleukin-2 (Collaborative Research, Inc., Waltham, Mass.),
and Prostaglandin E-. (Sigma Chemicals, St. Louis, Misouri). Each of




ABMP (100 m ic r og r ams/ml) 







Interferon (10 units/ml) + Interleukin-2 (10 units/ml)9)
Interferon (100 units/ml) + Interleukin-2 (10 units/ml)10)
-7ABMP (100 micrograms/ml) + Prostaglandin E-^ (1 x 10 M)
ABMP (100 micrograms/ml) + Interleukin-2 (10 units/ml)
Interferon (100 units/ml) ---- > Prostaglandin E^ (1 x 10 ^M)
Interferon (100 units/ml) + Interleukin-2 (10 units/ml) ---- >
Prostaglandin (1 x 10 "^M)
Prostaglandin E^ (1






Thus there were 60 test groups (4 spleen cell groups x 15 treatment groups).
In the following procedures all incubations were carried out at 37 
degrees centigrade in a 5% C09 atmosphere. The spleen cells were
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incubated with the specified biological response modifier at the
specified concentrations and combinations for 2 hours except in
treatments 13, 14, and 15. In these treatments the effector cells were
incubated with the first biological response modifier for 1 hour, a
:• r.onse mocifier was added and the cellsv.i.ich tne sec on biologica]
incubated for a secono hour. This procedure is indicated by ---->.
Cytotoxicity Assays
1) Preparation of Tamet Cells
Labeled H238 cells adjusted to a of 5 x 10^ 
cells/ml were dispensed in C.l ml aliquots into wells of a 96 well
H238 assay system.
microtiter plate (Falcon Plastics), such that the final cell
3concentration was 5 x 1CT cells/well. The plates were then incubated
for 2 hours to allow for cell attachment to the bottom of the wells.
Labeled K562 cells adjusted to a concentration 
of 5 x 10^ cells/ml were dispensed in 0.1 ml aliquots into wells
K562 assay system.
of a 96 well microtiter plate such that the final cell concentration 
was 5 x 10^ cells/well. The plates were then incubated for 2 hours.
2) Adaition of Effector Cells
H238 assay system. Hie plates containing the labeled H238 cells
were inverted and drained to remove any unattached cells (after the 2
hour incubation time). RPflI-1640 medium (0.1 ml) was immediately added
to stabilize the pH of the cells milieu. Effector cells, both tumor
and control (nontumor cell-injected), adjusted to a concentration of 6 
x 106 cells/ml were added to each well in 0.2 ml aliquots to produce an
effector cell to target cell ratio of 240:1.
K562 assay system. The plates containing the labeled K562 cells
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were removed from the incubator after the 2 hour incubation period.
Effector cells, both tumor and control, adjusted to a concentration of 
66 x 10 cells/ml, were then added to each well m 0.2 ml aliquots to 
produce a total effector to target cell ratio of 480:1. It should be
realized that since the NK population of the spleen is only
approximately 5% of the total cell population, this ratio represents an
actual effector cell to target cell ratio of approximately 24:1.
After the addition of the effector cells, all plates were
centrifuged at 80 x G for 3 minutes to allow closer cell to cell
contact, and incubated for 18 hours.
All samples were done in triplicate, except the nonspecific or
spontaneous lysis control (control to differentiate between lysis
mediated by effector cells and spontaneous lysis due to target cell
processing-expressed as MFC in formula section) in which only target
cells (5000 for H238 system, and 2500 for K562 system) and media (0.3
ml/well total) were added to each well. The nonspecific lysis control 
was allotted 6 wells/assay/target cell system.
Natural effector cell activity was expressed against both H238 and
K562 target cells. This control utilized cells from the non tumor cell-
injected control mice in order to establish a normal non modulated
response against either the H23 8 or K562 target cell, depending upon
the particular target system. In the H238 system this control was
necessary in order to differentiate between the specific and
nonspecific aspects of the immune response against the H238 target
cells. In the K562 assay system this control was utilized to determine
if there were differences in nonspecific immune response between normal
16
In both systems the net activity of theand tunion' cell-injected mice.
spleen cells from tumor cell-injected mice was deteririined by 
subtracting from the total % lysis the activity of the spleen cells
from non tumor cell-injected mice.
3) Cell Harvest
At the ena of the IS hour incubation period mentioned above, the
plates were harvested with a Multiple Automatic Sample Harvester (MASH
Bethesda, Maryland). The fluidII, Microbiological Associates, Inc • /
contained in the wells, after being passeo through filters capable of
filtering out any unattached cells, was collected into a first set of
The radioactivity in these tubes was counted in atubes (supernatant). 
gamma particle counter (Searle Scientific Instuments, Chicago, Ill.),
and was assumed to be the result of lysis of labeled target cells.
St. Louis, Mo.) was thenSodium dodecyl sulfate (Sigma Chemical Co 
added to the wells to lyse any remaining attached cells. This
• r
radioactivity was collected into a second set of tubes into which the
filter paper discs, used initially to collect the unattached whole
The sum of radioactivity contained in bothcells, were also added.
sets of tubes, expressed in counts/minute, provided the total cpm.
Tumor Volume Measurement
Weekly measurements of tumor size were made for each test animal
The following formula
3
tumor volume (mm) = (L x W x H)/2
included in the study, using Vernier calipers.
was used to determine tumor volume:
where L, W, ana H represent the length, width, and height of the tumor.
Formulas Used in Cvtotoxicitv Assays
1 MFC (mean release control)- Control to determine magnitude of
17
Only labeled target cells and medium 
% MjRC = [cpi (supernatant)/cpn (total)] x 100.
spontaneous lysis of target cells.
were added to the well.
2) ^ CR (control release)- Control to determine the extent of
natural effector activity in the H238 assay system, and to determine the 
baseline level of activity in the K562 system. In both cases the effector 
cells, control lymphocytes (CL), came from non tumor cell-injected mice.
% CR = [cpn (supernatant CL)/cpn (total CL)]-[% MRC/(100-% MRC)] x 100.
3) & CTL (cytotoxic T-lynphocyte)- Assay to determine the extent of
specific lysis of labeled H238 target cells by antigen-sensitized 
cytotoxic T-lynphocytes. The effector cells (IL) were from tumor
cell-injected mice.
Total % CTL = [cpn (supernatant IL)/cpi (total IL)]-[% MRC/(100-% MRC)] x 100.
Net % CTL = Total % CTL - % CR
4) d. NK (natural killer)- Assay to determine the extent of natural 
killer cell activity. Effector cells were from tumor cell-injected mice. 
Total % NK = [cpn (supernatant NK)/cpn (total NK)]-[% MRC/(100-% MRC)] x 100.
Net % NK = Total % NK - % CR.
Statistical Analysis
The data were subjected to multivariate analysis (analysis of 
variance) using a Hewlett Packard model 86 computer with software
written for the purpose.
RESULTS
Results
1) Cytotoxic T-Lymphocyte Assay. Results from the In vitro 
treatment of the spleen cells from the mice which were not tumor cell- 
injected (control mice) are shewn in Figures 1 (Diet 1), and 2 (Diet 8). 
The results are conpared in Table 1. From Table lit appears that the 
spleen cells from the non tumor cell-injected mice fed Diet 8 were 
more readily stimulated by the biological response modifiers than were 
the spleen cells from the Diet 1 non tumor cell-injected mice. 
Treatments 6 (IL2(2)), 12 (ABMP+IL2(10)), 14 (IF(100) + IL2(10)----
>PGE) f and 15 (PGE---- >IF(100) + IL2(10)) appeared to elicit the
greatest response in both diet groups, while treatment 2 (IF(100))
elicited the lowest response in both groups.
The net % CTL results for the tumor-injected mice are shewn in
The data shew a general divergence of net % CTLFigures 8 through 22.
This correlates well with the data on theactivity at or about day 20. 
change in tunor volume displayed in Figure 5. 
injected mice fed Diet 8 have a greater rate of increase in tumor 
volume than do the tunor cell-injected mice fed Diet 1 (Figure 5) .
After day 20 tumor cell-
All
of the Diet 1 groups show a greater net % CTL than do the Diet 8
groups, but only treatments 6 (IL2(2)), 8 (IL2(30)), 13 (IF(100)--
>PGE), and 14 (IF(100) + IL2(10)---->PGE) show a significant difference
at the p=.05 level, and only treatment 10 (IF(100) + IL2(10)) showed a 
significant difference at the p=.01 level.
The general trend in all treatments regardless of diet is for the
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net % CTL to decrease (often to negative values) in the last 10 to 15
days of the study.
2) Natural Killer Cell (NK) Assay. Results obtained from the In vitro
response modification of the spleen cells of the non tumor cell-injected 
mice are shewn in figures 3 (Diet 1) and 4 (Diet 8). Hie results are
From Table 2 it seems that the spleen cellscontrasted in Table 2.
from the non tumor cell-injected mice fed Diet 1 were more easily
stimulated to lyse the K562 target cells than were the spleen cells
from the non tumor cell-injected mice fed Diet 8. Treatments 6
(IL2(2)) and 14 (IF(100) + IL2(10)---->PGE) seemed to elicit the
greatest response in both the Diet 1 and Diet 8 groups.
Hie results for the net % lysis in the NK assay obtained for the 
tumor cell-injected mice are displayed in Tables 3 and 4. 
inspection of these tables it can be seen that there were no 
appreciable differences or trends between the In vitro stimulation
Upon
level (net % NK lysis) of the spleen cells obtained from the Diet 1 and
Both groups seem to exhibit approximatelyDiet 8 tumor bearing mice.
the sane net % NK cytotoxicity at similiar times post tumor injection.
Tumor Volume
Weekly calculations of tumor volume were made for each tumor
The results of thesebearing mouse included in the experiment.
measurements (which includes data from all tumor cell-injected mice)
No tumors were found in the non tumor cell-are depicted in Figure 5.
Tumors began to appear in bothinjected mice throughout the study.
groups (Diet 1 and Diet 8) at approximately day 7 after the injection
The rate of increase in tumor size is almostof the H238 tumor cells.
20
identical until day 20 at which time the tumors borne by the animals
fed Diet 8 began to increase at a much greater rate than the tumors on
the animals being fed Diet 1. In both groups, however, once the tumors
began to develop, a weekly increase in mean tumor volume was observed.
21
TABLE 1. COMPARISON OF TOTAL % LYSIS OF 11238 
TARGET CELLS BY EFFECTOR CELLS OBTAINED FROM 
THE SPLEENS OF MICE FED EITHER A DIET LOO IN 
UNSATURATED FAT (DIET 1) OR A DIET1 HIGH IN 
UNSATURATED FAT (DIET 8) AID TREATED IL VITRO 
AS INDICATED
% LYSIS OF TARGET1 CELLS
TREATMENT DIET 1 DIET 8
1. IF(10) 38.2 38.5
2. IF(100) 35.0 35.6
3. IF(1000) 37.8 36.6
4. ABMP 37.0 38.7
5. PGE 37.7 38.5
6. IL2(2) 37.1 38.7
7. IL2(10) 44.4 45.3
8. IL2(30) 39.0 39.9
9. IF(10)+IL2(10) 38.0 38.9
10. IF(100)+IL2(10) 36.5 41.7
11. ABMP+PGE 38.5 41.8
12. ABMP+IL2(10) 40.8 43.5
13. IF(100)—>PGE 36.9 40.1
14. IF(100) +IL2(10)—>PGE 42.2 47.0
15. PGE—>IF(100)+IL2(10) 43.9 46.2
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COMPARISON OF TOTAL % LYSIS OF K562TABLE 2.
TARGET CELLS BY EFFECTOR CELLS OBTAINED FROM 
THE SPLEENS OF MICE FED EITHER A DIET LOW IN 
UNSATURATED FAT (DIET 1) OR A DIET1 HIGH IN 
UNSATURATED FAT (DIET 8) THEN TREATED XL VITRO 
AS INDICATED.
% LYSIS OF TARGET CELLS
DIET 1 DIET 8TREATMENT
1. IF(10) 32.9 31.3
2. IF(100) 32.0 31.2








11. ABMP+PGE 31.7 31.4
12. ABMP+IL2(10) 32.934.0




TABLE 3. NET % CYTOTOXICITY OP EFFECTOR CEILS 
AGAINST K562 CELLS AT SPECIFIED TIME POST TUMOR 
CELL-INJECTION.
FROM THE SPLEENS OF TUMOR CELL-INJECTED MICE 
FED A DIET HIGH IN UNSATURATED FAT (DIET 8)
THEN TREATED VITRO AS INDICATED.
EFFECTOR CELLS I/ERE OBTAINED
DAYS AFTER H238 TUMOR CEIL INJECTION
16 20 23 26 29 36 439 49TREATMENT
IF(10) 6.0 8.21. -1.6 1.0 0.5 -0.4 -2.8 -5.0 -1.4
-4.2 2.1 2.1 2.22. IF(100) -0.2 -0.1 -1.5 0.5 0.1
-3.13. IF(1000) -1.6 -8.4 -2.4 -2.8 8.0 -1.02.3 -1.4
-0.3 0 4.64. -2.9 1.1 -2.2 -4.3 -1.8 0ABMP
5. 0.2 -0.3 0.4 -1.0 9.4-1.8 -2.4 -6.0 -2.5PGE
IL2(2)6. 0.6 0.5 -1.7 -1.2 -3.4 -5.6 5.9 -1.8-1.9
7. IL2(10) -0.710.5 1.1 -3.4 -4.0 -2.0 -4.9-4.0 -4.5
-3.88. IL2(30) -0.1 -1.7 -2.6 -3.4 -5.47.8 -1.8 1.2
IF(10)+IL2(10)9. 1.7 2.2 0.2 8.8 2.62.4 -6.5 -1.8 -0.1
10. IF(100)+IL2(10) 0.1 -1.7 4.3 -2.1-0.9 -0.6 1.0 0.22.5
11. ABMP+PGE 2.0 -0.7 -0.5 7.1 0.4-2.8 1.2 -2.2 0.8
12. ABMP+IL2(10) -0.4 -2.5 6.0 1.32.6 -1.2 -1.4 -4.5 0




2.7 -1.0 -0.5 -2.8 -1.3 5.6 0.90.4 -5.1
15. PGE—>
IF(100)+IL2(10) 0.4 11.3-2.3 2.6 -2.9 -1.3 0.3 -0.5-1.1
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TABLE 4. NET % CYTOTOXICITY OF EFFECTOR CELLS 
AGAINST K562 TARGET CEILS AT SPECIFIED TIME 
POST TUMOR CELL-INJECTION. EFFECTOR CELLS 
WERE OBTAINED FROM THE SPLEENS OF TUMOR CELL- 
INJECTED MICE FED A DIET’ HIGH IN UNSATURATED 
FAT (DIET 8) THEN IN VITRO AS INDICATED.
DAYS AFTER H238 CEIL INJECTION
16 20 23 26 29 36 43 49TREATMENT 9
1. IF(10) 3.2 -0.8 1.6 2.4 3.1-1.6 -2.5 6.9 2.5
2. IF(100) -0.2 0.3 -1.2 0.3 0.5 0.9-0.2 8.9 -0.1
3. IF(100) -1.6 -0.3 -2.6 -0.11.7 -1.9 -0.9 9.8 1.5
4. ABMP -2.9 -0.3 0 -0.6 -0.6 -0.5 0.6 7.0 6.8
5. PGE 0.2 2.7 -2.1 -3.9 -2.1 -0.2 -0.6 5.2 -0.7
6. IL2(2) 0.6 0.8 0 0.5 -0.9 -2.3 0.8 9.0 0
7. IL2 (10) 10.5 -1.6 0.1 3.5 4.7 5.8 -4.3 1.7 9.1
8. IL2(30) -0.1 19.4 11.8 -0.6 -1.9 -3.2 -1.4 -4.0 -1.5
9. IF(10)+IL2(10) 2.4 2.1 3.2 1.3 0.7 0 -4.4 8.0 0.6
10. IF(100)+IL2(10) 0.1 2.6 2.7-1.1 2.2 -0.5 -3.2 2.1 2.7
11. ABMP+PGE 2.0 2.4 0.90 0.7 1.1 -1.4 6.2 0
12. ABMP+IL2(10) 2.72.6 0.1 1.0 1.8 3.2 4.50.2 -0.3
13. IF(100) —>PGE 1.1 2.7 1.8 -0.6 8.50.7 2.0 -5.0 -0.9
14. IF(100)+11.2(10) 
—>PGE 1.7 -2.72.7 -4.2 -8.4 3.1 -10.9 6.9 -2.4
15. PGE—>
IF(100) +IL2 (10) -2.3 1.5 8.6 -3.2 -2.1 -1.0 -1.7 6.5 -1.9
fO
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FIGURE 1. BIOLOGICAL RESPONSE MODIFICATION CONTROL. 
TOTAL CYTOLYTIC ACTIVITY EXPRESSED BY EFFECTOR CELLS 
AGAINST H238 TARGET CELLS. EFFECTOR CELLS WERE OBTAINED 
FROM THE SPLEENS OF NON TUMOR CELL-INJECTED MICE FED A 
DIET La/ IN UNSATURATED FAT (DIET 1) AND TREATED IL VITRO 
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FIGURE 1. BIOLOGICAL RESPONSE MODIFICATION OF EFFECTOR CELLS FROM NON TUMOR-INJECTED MICE FED 




TOTAL CYTOLYTIC RESPONSE EXPRESSED BY EFFECTOR CELLS 
AGAINST H238 TARGET CELLS. EFFECTOR CELLS WERE OBTAINED 
FROM THE SPLEENS OF NON TUMOR CELL-INJECTED MICE FED A 
DIET HIGH IN UNSATURATED FAT (DIET 8) THEN TREATED IN 
VITRO WITH THE INDICATED MODULATOR.
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FIGURE 2. BIOLOGICAL RESPONSE MODIFICATION OF EFFECTOR CELLS FROM NON TUMOR-INJECTED MICE FED 
DIET 8 (H238 ASSAY SYSTEM)
NJ
FIGURE 3. BIOLOGICAL RESPONSE MODIFICATION. TOTAL 
CYTOLYTIC RESPONSE OF EFFECTOR CELLS AGAINST K562 TARGET 
CELLS. EFFECTOR CELLS WERE OBTAINED FROM THE SPLEENS OF 
NON TUMOR CELL-INJECTED MICE FED A DIET LOW IN UNSATURATED 
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FIGURE 3. BIOLOGICAL RESPONSE MODIFICATION OF EFFECTOR CELLS FROM NON TUMOR-INJECTED MICE FED 
DIET 1 (K562 ASSAY SYSTEM)
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FIGURE 4. BIOLOGICAL RESPONSE MODIFICATION. TOTAL 
CYTOLYTIC RESPONSE EXPRESSED BY EFFECTOR CELLS AGAINST 
K562 TARGET CELLS. EFFECTOR CELLS WERE OBTAINED FROM THE 
SPLEENS OF TUMOR CELL-INJECTED MICE FED A DIET HIGH IN 
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FIGURE 4. BIOLOGICAL RESPONSE MODIFICATION OF SPLEEN CELLS FROM NON TUMOR-INJECTED MICE FED 
DIET 8 (K562 ASSAY SYSTEM)
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FIGURE 5. OT1CF VOLUME FROM ALL TUMOR CELL-INJECTED MICE. 
DIET 1 INDICATES A DIET LOW IN UNSATURATED FAT, WHILE DIET 
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DAYS AFTER H238 CELL INJECTION
OJFIGURE 5. TUMOR VOLUME AT TIME AFTER TUMOR INJECTION 4^
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NET % LYSIS EXPRESSED BY EFFECTOR CELLS AGAINSTfigure: 6.
H238 TARGET1 CELLS. EFFECTOR CELLS WERE OBTAINED FROM THE
SPLEENS OF TUMOR CELL-INJECTED MICE FED A DIET LOW IN 



















-%5 1 JL-L J__L-J.10 15 20 25 30 35 40 45 50
DAYS AFTER H238 TUMOR CELL INJECTION
u>
FIGURE 6. NET % LYSIS OF TARGET CELLS BY EFFECTOR CELLS FROM TUMOR-INJECTED MICE FED 
DIET 8. NO BIOLOGICAL RESPONSE MODIFICATION.
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FIGURE 7. NET % LYSIS EXPRESSED BY EFFECTOR CELLS AGAINST 
H238 TARGET CELLS. EFFECTOR CELLS WERE OBTAINED FROM THE 
SPLEENS OF TUMOR CELL-INJECTED MICE FED A DIET HIGH IN 
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FIGURE 7. NET % LYSIS OF TARGET CELLS BY EFFECTOR CELLS FROM TUMOR-INJECTED MICE FED 
DIET 8. NO BIOLOGICAL RESPONSE MODIFICATION.
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NET % LYSIS OF H238 TARGET CELLS BY EFFECTORFIGURE 8.
CELLS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR HIGH IN 
UNSATURATED FAT (DIET 8) AND TREATED IN VITRO WITH 
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FIGURE 8. INTERFERON (10 UNITS/ML)
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FIGURE 9. NET % LYSIS OF H238 TARGET CELLS BY EFFECTOR 
CEILS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR A DIET 
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FIGURE 9. INTERFERON (100 UNITS/ML) NJ
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FIGURE 10. NET % LYSIS OF H23 8 TARGET CELLS BY EFFECTOR 
CELLS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR A DIET 
HIGH IN UNSATURATED FAT (DIET 8) AID TREATED IN VITRO WITH 
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FIGURE 10. INTERFERON (1000 UNITS/ML)
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FIGURE 11.
CELLS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR HIGH IN 
SATURATED FAT (DIET 8) AND TREATED HI VITRO WITH ABMP.














5 10 15 20 25 30 35 40 45 50
DAYS AFTER H238 TUMOR CELL INJECTION
FIGURE 11. 2-amino, 5-bromo, 6-methyl, 4-pyriminone (ABMP) (100 MICROGRAMS/ML) 4^
FIGURE 12. NET % LYSIS OF 11238 TARGET CELLS BY EFFECTOR 
CELLS WHICH WERE OBTAINED FORM THE SPLEENS OF MICE WHICH 
WERE FED EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR 
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FIGURE 12. PROSTAGLANDIN El (1 x 10 7M)
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FIGURE 13. NET % LYSIS OF H23 8 TARGET CELLS BY EFFECTOR 
CEIXS WHICH V7ERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR HIGH IN 
UNSATURATED FAT (DIET 8) AND TREATED XN VITRO WITH 
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NET % LYSIS OF H23 8 TARGET CELLS BY EFFECTORFIGURE 14.
CELLS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR HIGH IN 
UNSATURATED FAT (DIET 8) AND TREATED JM VITRO WITH 
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FIGURE 15. NET % LYSIS OF H23 8 TARGET CELLS BY EFFECTOR 
CELLS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR HIGH IN 
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CELLS WHICH WERE OBTAINED FROM THE SPIEENS OF MICE FED 
EITHER A DIET LOW IN UNSATUIATED FAT (DIET 1) OR HIGH IN 
UNSATURATED FAT (DIET 8) AND TREATED IN VITRO WITH 
INTERFERON (10 UNITS/ML) + INTERLEUKIN-^ (10 UNITS/ML).




FIGURE 17. NET % LYSIS CF H238 TARGET CELLS BY EFFECTOR 
CELLS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR HIGH IN 
UNSATURATED FAT (DIET 8) AND TREATED JLN VITRO WITH 
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FIGURE 17. INTERFERON (100 UNITS/ML) + INTERLEUKIN-2 (10 UNITS/ML) co
Ln
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FIGURE 18. NET % LYSIS OF H238 TARGET CELLS BY EFFECTOR 
CEIXS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR HIGH IN 





FIGURE 19. NET % LYSIS OF H23 8 TARGET CELLS BY EFFECTOR 
CEILS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSAURATED FAT (DIET 1) OR HIGH IN 
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FIGURE 19. ABMP (100 MICROGRAMS/ML) + INTERLEUKIN-2 (10 UNITS/ML) fo
cn
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FIGURE 20. NET % LYSIS OF H23 8 TARGET CELLS BY EFFECTOR 
CELLS WHICH WERE OBTAINED FROM MICE FED EITHER A DIET LCW 
IN UNSATURATED FAT (DIET 1) OR HIGH IN UNSATURATED FAT 
(DIET 8) Art) TREATED IN VITRO WITH INTERFERON FOR 1 HOUR 















DAYS AFTER H238 TUMOR CELL INJECTION
INTERFERON (100 UNITS/ML) —> PROSTAGLANDIN El (1 x 10 7M)FIGURE 20. 4^
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FIGURE 21. ^JET % LYSIS OF H238 TARGET CELLS BY EFFECTOR 
CELLS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR HIGH IN 
UNSATURATED FAT (DIET 8) AND TREATED JLU VITRO WITH 
INTERFERON + INTERLEUKIN-2 FOR 1 HOUR THEN PROSTAGLANDIN 
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Figure 21.
INTERFERON (100 UNITS/ML) + INTERLEUKIN-2 (10 UNITS/ML) —> PROSTAGLANDIN El (1 x 10 7M) CK<T)
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FIGURE 22. NETT % LYSIS CF H23 8 TARGET CELLS BY EFFECTOR 
CEILS WHICH WERE OBTAINED FROM THE SPLEENS OF MICE FED 
EITHER A DIET LOW IN UNSATURATED FAT (DIET 1) OR HIGH IN 
UNSATURATED FAT (DIET 8) AND TREATED IN VITRO WITH 
PROSTAGLANDIN E, FOR 1 HOUR THIN INTERFERON + INTERLEUKIN- 
2 FOR 1 HOUR.

'T If:
Oncogenesis is acconpeinied by the appearence of tumor-associated
cellular neoantigens. The immune cells of the host can frequently
recognize these surface antigens as "non-self" and under certain
This is the basic tenet of theconditions inhibit tumor progression.
immune surveillance theory put forward by Burnet (1971) . The purpose
of such a mechanism would be to prevent the emergence of mutant
malignant cells. Although the generality and the significance of the
immune surveillance theory have been questioned (Kriple and Boros,
1974; Prehn, 1976, 1977), the phenomenon is generally accepted as a
primary defense against neoplastic development (loachim, 1976; Allison,
1977) .
One of the requirements of the immune surveillance mechanism is
that the immune system of the host be able to recognize and respond to
the tumor antigen (i.e. the host must be immunologically competent
(Stites et. al., 1983). This is usually the point where the immune
surveillance theory breaks dov/n, for the immune system of the tumor­
bearing host is often compromised by the tumor. Tumor
immunosuppressive mechanisms include: 1) serum blocking antibodies
that are specific for the tumor antigens and able to bind to the
antigen but cannot bind complement; they are, therefore, unable to lyse
the target and block other active antibodies from attaching to the site
(Chard, 1968; Broder and Whitehouse, 1968; Hellstrom and Hellstrom,
2) soluble antigens shed by tumor cells which react with1969),
specific antibodies to form antigen-antibody complexes or directly 
block T-cell receptor sites that could otherwise react with antigens on
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the tumor itself (Sjogren et. al.f 1971; Baldwin and Price, 1972;
1972; Oldstone, 1975, 3) activation of suppressor T-Brooks et. al » f
lynphocytes tiiat mediate either specific or general immunosuppression
in response to the tumor antigen (Taussig, 1974; Kirehner and Chused,
1974; Fujimoto et. al 1975; Glaser and Kirchner, 1975; Greene and• r
Fujimoto, 1977) , and 4) soluble factors that mediate suppression of
the host immune response (Katzmann, 1978; Pennline and Evans, 1979;
Havas and Schiffnan, 1979; Kumor et. al 1981a, 1981b). These are• r
only the general mechanisms. Published reviews deal more in depth with
these topics (Kamo and Friedman, 1977; Fidler et. al 1978) .• r
Any combination of the above immunosuppressive mechanisms could be
responsible for the general trend of depressed immune response as a
function of time as measured in the CTL assay. Data from our
laboratories have sugggested that the H238 tumor cells release an
immunosuppressive factor into the culture medium able to confer a state
of lowered responsiveness on effector cells obtained from non-tumor
bearing mice (Gridley, unpublished results).
Oie of the main objectives of this study was to examine different
ways of enhancing the immune response in immunosuppressed mice via
biological response modifiers. All of the in vitro interferon
treatments (10, 100, and 1000 units/ml-Figures 8-10) for both the Diet
1 and 8 groups show an increase in cytotoxicity (as measured in the CTL
assay) over the control group (non-modulated effector cells obtained
from tunor cell-injected mice) depicted in Figures 6 and 7 for Diets 1
and 8 respectively. The effector cells from mice fed Diet 1 shov; a
general trend of higher CTL, lysis over the effector cells from mice fed
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Diet 8, but only at 1000 units of interferon/ml (Figure 3) do the Diet
1 effector cells show a sustained level of higher CTL past day 20.
Detween days 23 and 30 the effector cells from mice fed Diet 1 appear 
to respond in a dose related fashion with 10 units/ml> 100 units/ml > 
The significance of this observation, if any, is1000 units/ml.
unknown.
The in vitro interleukin-2 treatments (Figures 11-13) were also
able to increase the cytotoxicity of the effector cells above that of
the control groups (Figures 6 and 7). Once again, the effector cells
from mice fed Diet 1 appeared to be more sensitive to modulation than
Treatment of effector cellsthe effector cells from mice fed Diet 8.
from mice fed Diets 1 and 8 with interleukin-2 at 2 units/ml and 30
units/ml (Figures 11 and 13) showed significant differences in
We see thecytotoxicity between Diets 1 and 8 at the p=.05 level, 
trend toward immunosuppression in Figures 12 and 13 (10 and 30 units of 
interleukin/ml), but the trend is not obvious at 2 units/ml. The
reason for, and significance of, this observation is not known. The 
general trend toward lowered CTL values seen in most of the graphs is, 
however, quite understandable when one considers that at this point the
host was presumably approaching immune dysfunction due to the 
immunosuppressive mechanisms initiated by the tumor presence and load. 
It is quite probable that had the mice not been euthanized when they
Thewere, they would have expired due to the enormous tumor load.
divergence of the results for the mice fed Diet 1 versus the mice fed
Diet 8 at or about day 20 is especially prominent in Figures 11 and 13. 
This, as mentioned earlier, can be correlated with the rate of change
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It is possible that the tumor inof tumor volume depicted in Figure 5.
the mice fed Diet 8, growing at a greater rate than the tumor in the
mice fed Diet 1, elaborates more immunosuppressor factors, or activates
more immunosuppressive mechanisms than does the tumor in the Diet 1
group. The presence of the immunosuppressive factors may be expressed
as a lowered level of lysis in the CTL assay.
The combination of interferon and interleukin-2 (Figures 16 and
Figure 16 represents the17) gives rise to some interesting results, 
combination of 10 units of interferon/ml with 10 units of interleukin-2/
In Figure 17, the interleukin-2 level remained the same but theml.
interferon level was raised to 100 units/ml. In both combinations the
levels of cytotoxicity attained by the effector cells from mice fed
Diet 1 are essentially the same, both higher than the levels of
cytotoxicity expressed by the effector cells from mice fed Diet 8. 
Fran the similarity of the Diet 1 graphs in both Figures 16 and 17 , it
seems likely that if some cytotoxic mechanism is being triggered, 10
units of interferon/ml is sufficient to activate it.
The Diet 1The jp vitro ABMP treatment is shown in Figure 11.
graph has too much variation to make comparison with the Diet 8 graph
In Figures 18 and 19 we see the combination of ABMP withmeaningful.
prostaglandin and interleukin-2 respectively, 
almost identical, for both Diets 1 and 8, with the effector cells from
These two graphs are
the mice fed Diet 1 cells maintaining a higher level of net CTL lysis
than the effector cells from mice fed Diet 8. Comparing Figure 19,
ABMP (100 micrograms/ml) + interleukin-2 (10 units/ml) with Figure 14 
(interleukin-2, 10 units/ml), there appears to be a loss of CTL
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activity when ABMP is combined with interleukin-2 as compared with
The same type of results were observed when
~7comparing ABMP (100 micrograms/ml) + prostaglandin (lx 10 M) with
-7prostaglandin (1 x 10 M) alone, 
was more effective than the combination treatment.
interleukin-2 alone.
Once again the single treatment
The general trend
of higher net CTL lysis by effector cells from mice fed Diet 1 is also
observed here.
The final treatment combinations, the temporal treatments, are
shewn in Figures 20-22. The strategy was to affect (with a primary
modulator) an initial change in the effector cell, presumably via
modulator binding to regulatory molecules on the cell surface, which in
turn cause internal changes. These initial internal changes, in 
effect, set the stage for the action of the secondary modulator, which
boosts the lytic capability of the effector cell in excess of the level
that could be attained with either modulator alone.
Of the three temporal modulation treatments the most effective
appears to be interferon (100 units/ml) + interleukin-2 (10 units/ml) — 
-> prostaglandin E-^ (1 x 10 ^M) (Figure 21), in which the level of 
cytotoxicity of effector cells from mice fed Diet 1 is significantly 
different from the level of cytotoxicity of cells obtained from mice
fed Diet 8 at the p^.OS level.
—7of interferon (100 units/ml) ---- > prostaglandin E-^ (1 x 10 M) , the
level of cytotoxicity achieved by effector cells from mice fed Diet 1
In Figure 20, which depicts the effects
is also significantly different from the level of cytotoxicity attained
by the effector cells from the mice fed Diet 8 at the p=.05 level but
does not reach the level of activity attained by comparable effector
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cells in Figure 21.
Hie source of dietary fat utilized in this study was corn oil, a
Unsaturated fats have been shown to have a widepolyunsaturated fat.
spectrum of effects on the immune system which include: 1) depressed
m vitro lymphocyte response to certain antigens and mitogens, 2)
depression of reticuloendothelial clearance of particulate matter, 3)
inhibition of neutrophil chemotactic and phagocytic function, 4)
inhibition or delay of graft-versus-host responses, 5) alteration of
lipid content of phagocytic and lymphoid cells, 6) alteration of
rosette forming capability of lynphocytes, and 7) decreased rejection
crisis in renal transplant patients (Beisel, 1981; Nev/berne, 1981).
Clearly, dietary and endogenous lipids influence immunocompetence and.
in this manner, probably susceptibility to cancer.
Hie results outlined in the preceeding text shew that the effector
cells from mice fed the diet low in fat (Diet 1) consistantly exhibited
a greater net CTL than the effectors from the mice fed the diet high in
It may be that the cytotoxic T-lymphocytes from all thefat (Diet 8).
BALB/c mice have lipoprotein immune receptors on their cell surface
which are sensitive to the level of dietary fat in the plasma (which is
When the level of dietary fat isa function of dietary fat intake) .
too high, perhaps the configuration of the lipid portion of these
receptors is altered, due to an improperly high plasma lipid level
resulting in a decreased affinity of the receptor for the biological 
response modulator. This mechanism offers one possible explanation 
for the observation of consistently lower levels of cytotoxicity 
achieved by effector cells from mice fed Diet 8 as compared to effector
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cells from mice fed Diet 1. Another mechanism which could possibly
explain the observation include elevated levels of the lipoproteins
with a density less than 1.063 g/rnl (LDL) , which have been indirectly
correlated with suppressed immune function (Chandra, 1981; Newberne and
Thurman, 1981). High levels of plasma lipid have been reported to alter
the fluidity of the lymphocyte cell membrane resulting in lowered
responsiveness (Vitale and Broitmann, 1981) . This phenomenon could
also be at least partially responsible for the lowered responsiveness
of the effector cells detained from the mice fed the high fat diet.
CONCLUSIONS
This study appeared to indicate that spleen cells derived from
mice bearing H238 tumors were more responsive to certain biological
response modifiers (as measured in CTL assays) when the mice were fed a
diet low in unsaturated fat (5% corn oil) with casein as the protein
source (Diet 1) as opposed to a diet high in unsaturated fat (30% corn
oil) with wheat gluten as the protein source (Diet 8).
Interleukin-2 appeared to be the most potent immune modulator of
the group studied, especially when combined with interferon. 
Prostaglandin was also quite effective in enhancing the cytotoxicity 
level of the effector cells when the cells were first treated with
either interleukin-2 alone or interleukin-2 in combination with
interferon.
Natural killer cell activity remained essentially unchanged
regardless of diet group or modifying treatment. This was possibly due
to the choice of the target cell used for the NK assay, the K562 line.
The MOLT-4 and YAC-1 cell lines are usually used for murine NK cell
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